Vitreous is very stable in highly acidic and alkaline conditions

Article

Vitreous has a greater buffering capacity than sodium chloride (0.9% NaCl), suggesting that it is able to remain more stable when acidic or alkaline pharmaceuticals are injected in microlitre amounts.

Vitreous has a greater buffering capacity than sodium chloride (0.9% NaCl), suggesting that it is able to remain more stable when acidic or alkaline pharmaceuticals are injected in microlitre amounts, according to a study published in the January issue of Retina.

Mandi Conway and colleagues from the University of Arizona College of Medicine, Department of Ophthalmology and Vision Science, Tucson, USA carried out a study to measure the buffering capacity of bovine vitreous to hydrogen chloride (HC1), sodium hydroxide (NaOH) and triamcinolone acetonide.

Vitreous was dissected from 10 bovine globes, homogenized and divided into 5 mL aliquots. The carbonate/bicarbonate buffer of the vitreous was maintained by performing all subsequent titrations under an atmosphere of 5% CO2/95% air. The pH was monitored during the addition of 0.1 N HC1, 0.1 N NaOH or 40 mg/mL triamcinolone acetonide to the vitreous sample; 0.9% NaC1 was used as a control.

The researchers found that the buffering capacity of bovine vitreous to HC1 was 10 times greater than that of 0.9% NaC1 and that the buffering capacity of vitreous to NaOH was four times greater than that of 0.9% NaC1. It was also discovered that bovine vitreous was able to resist pH changes from addition of triamcinolone acetonide at levels 20 time greater than commonly injected intravitreally.

The results of this study indicate that vitreous is more capable of remaining stable when acidic or alkaline pharmaceuticals are injected into it.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.